Blood markers may predict dangerous transplant complication

NCT ID NCT01520623

Completed Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 70 patients who had a stem cell transplant for blood cancer. Researchers measured levels of complement proteins in the blood to see if they are linked to graft-versus-host disease, a common and serious side effect. The goal is to better understand how inflammation affects transplant success and find new targets for treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could point toward new ways to prevent or treat graft-versus-host disease without weakening the anti-cancer effect of the transplant.
What could go wrong: This is an observational study, not a treatment trial. It only measures biological markers, so it cannot directly prove any new therapy works. The results may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGRAFTED WITH MYELOABLATIVE CONDITIONING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease hematopoietic and lymphoid cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLOGRAFTED WITH MYELOABLATIVE CONDITIONING

Contacts and locations

Locations

Necker Hospital

Paris, 75, France
Saint Antoine Hospital

Paris, 75012, France
Saint Louis Hospital

Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.